Arashdeep Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arashdeep Singh has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sridhar Hannenhalli
Cancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, 20814
7 shared publications - Vishaka Gopalan
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
3 shared publications Arati Rajeevan
Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, USA
2 shared publications- Cole Ruoff
Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications - David Y. Takeda
National Cancer Institute
2 shared publications - Dimple Notani
National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bengaluru, 560065, India
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (6) , 928-961
Identifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME
Tumor microenvironment (TME) is characterized by a milieu of distinct cell types that exist in heterogenous transcriptional states across tumors. Functional interactions among these cell states drive tumor progression and therapy response. Systematic characterization of functional cell-state interactions (CSIs) remains challenging due to the paucity of scRNA-seq cohorts with clinical information on one hand, and the lack of cellular context in bulk RNA-seq cohorts on the other. We present CSI-TME, a computational pipeline that extends the concept of gene interactions, such as synthetic lethality, to cell states, to infer prognostic CSIs by directly leveraging large cohorts of bulk transcriptomic datasets. Applied CSI-TME to IDH-mutant gliomas, we identified a highly reproducible cell-state interaction network (CSIN) that is predominantly pro-tumor and differentially activated in IDH-mut astrocytoma versus oligodendroglioma. Malignant cell states within the CSIN resemble multiple neuronal lineages, including astrocyte-like and oligodendrocyte-progenitor-like programs, and reveal key interactions between glioma stem cells and T cells. CSIN stratifies patient response to immune-checkpoint blockade therapy. Roughly 20% of CSIs involve direct ligand–receptor communication, and co-localize in spatial-transcriptomic datasets, most notably for a pro-tumorigenic interaction between tip-like endothelial cells and hypoxic malignant cells supported by multiple ligand–receptor interactions. Interestingly, anti-tumor CSIs correlated with oncogenic mutations are preferentially active in early stages of cancer, hinting at tissue homeostatic response. Overall, CSI-TME is a novel approach that, leveraging clinical bulk transcriptomic data, identifies prognostic CSIs and therapeutic ligand–receptor targets, while providing novel insight into how interactions among the cell states shape the TME in IDH-mutant glioma.
- 10 March 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (6) , 928-961
Open AccessIdentifying clinically relevant cell state interactions in the tumor microenvironment of IDH-mutant gliomas using CSI-TME
Tumor microenvironment (TME) is characterized by a milieu of distinct cell types that exist in heterogenous transcriptional states across tumors. Functional interactions among these cell states drive tumor progression and therapy response. Systematic characterization of functional cell-state interactions (CSIs) remains challenging due to the paucity of scRNA-seq cohorts with clinical information on one hand, and the lack of cellular context in bulk RNA-seq cohorts on the other. We present CSI-TME, a computational pipeline that extends the concept of gene interactions, such as synthetic lethality, to cell states, to infer prognostic CSIs by directly leveraging large cohorts of bulk transcriptomic datasets. Applied CSI-TME to IDH-mutant gliomas, we identified a highly reproducible cell-state interaction network (CSIN) that is predominantly pro-tumor and differentially activated in IDH-mut astrocytoma versus oligodendroglioma. Malignant cell states within the CSIN resemble multiple neuronal lineages, including astrocyte-like and oligodendrocyte-progenitor-like programs, and reveal key interactions between glioma stem cells and T cells. CSIN stratifies patient response to immune-checkpoint blockade therapy. Roughly 20% of CSIs involve direct ligand–receptor communication, and co-localize in spatial-transcriptomic datasets, most notably for a pro-tumorigenic interaction between tip-like endothelial cells and hypoxic malignant cells supported by multiple ligand–receptor interactions. Interestingly, anti-tumor CSIs correlated with oncogenic mutations are preferentially active in early stages of cancer, hinting at tissue homeostatic response. Overall, CSI-TME is a novel approach that, leveraging clinical bulk transcriptomic data, identifies prognostic CSIs and therapeutic ligand–receptor targets, while providing novel insight into how interactions among the cell states shape the TME in IDH-mutant glioma.
- Open Access
- 20 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10202
Non-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Prostate cancer (PrCa) incidence and severity vary across ancestries; men of African ancestry (AA) are more likely to be diagnosed and die from PrCa than those of European ancestry (EA). Current polygenic risk scores, even from multi-ancestry GWAS, do not fully capture population-specific genetic mechanisms, especially those mediated by non-coding regulatory single nucleotide polymorphisms (SNPs). Using a deep learning model of prostate enhancers, we identify ~ 2000 SNPs, potentially affecting enhancer function, with higher alternate allele frequency in AA men, that may affect PrCa risk. These SNPs may promote cancer via two mechanisms: increased enhancer activity leading to immune suppression and telomere elongation or decreased activity causing de-differentiation and apoptosis inhibition. Identified SNPs predominantly modulate binding of key transcription factors such as FOX, HOX, and AR – the first was experimentally validated. Incorporating these SNPs into a polygenic risk score improves PrCa risk assessment beyond existing GWAS-identified variants.
- 20 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10202
Open AccessNon-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Prostate cancer (PrCa) incidence and severity vary across ancestries; men of African ancestry (AA) are more likely to be diagnosed and die from PrCa than those of European ancestry (EA). Current polygenic risk scores, even from multi-ancestry GWAS, do not fully capture population-specific genetic mechanisms, especially those mediated by non-coding regulatory single nucleotide polymorphisms (SNPs). Using a deep learning model of prostate enhancers, we identify ~ 2000 SNPs, potentially affecting enhancer function, with higher alternate allele frequency in AA men, that may affect PrCa risk. These SNPs may promote cancer via two mechanisms: increased enhancer activity leading to immune suppression and telomere elongation or decreased activity causing de-differentiation and apoptosis inhibition. Identified SNPs predominantly modulate binding of key transcription factors such as FOX, HOX, and AR – the first was experimentally validated. Incorporating these SNPs into a polygenic risk score improves PrCa risk assessment beyond existing GWAS-identified variants.
- Open Access
- 26 August 2025
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 8, 44
Resistance signatures manifested in early drug response across cancer types and species
Aim: Growing evidence points to non-genetic mechanisms underlying long-term resistance to cancer therapies. These mechanisms involve pre-existing or therapy-induced transcriptional cell states that confer resistance. However, the relationship between early transcriptional responses to treatment and the eventual emergence of resistant states remains poorly understood. Furthermore, it is unclear whether such early resistance-associated transcriptional responses are evolutionarily conserved. In this study, we examine the similarity between early transcriptional responses and long-term resistant states, assess their clinical relevance, and explore their evolutionary conservation across species. Methods: We integrated datasets on early drug responses and long-term resistance from multiple cancer cell lines, bacteria, and yeast to identify early transcriptional changes predictive of long-term resistance and assess their evolutionary conservation. Using genome-wide CRISPR-Cas9 knockout screens, we evaluated the impact of genes associated with resistant transcriptional states on drug sensitivity. Clinical datasets were analyzed to explore the prognostic value of the identified resistance-associated gene signatures. Results: We found that transcriptional states observed in drug-naive cells and shortly after treatment overlapped with those seen in fully resistant populations. Some of these shared features appear to be evolutionarily conserved. Knockout of genes marking resistant states sensitized ovarian cancer cells to Prexasertib. Moreover, early resistance gene signatures effectively distinguished therapy responders from non-responders in multiple clinical cancer trials and differentiated premalignant breast lesions that progressed to malignancy from those that remained benign. Conclusion: Early cellular transcriptional responses to therapy exhibit key similarities to fully resistant states across different drugs, cancer types, and species. Gene signatures defining these early resistance states have prognostic value in clinical settings.
- 26 August 2025
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 8, 44
Open AccessResistance signatures manifested in early drug response across cancer types and species
Aim: Growing evidence points to non-genetic mechanisms underlying long-term resistance to cancer therapies. These mechanisms involve pre-existing or therapy-induced transcriptional cell states that confer resistance. However, the relationship between early transcriptional responses to treatment and the eventual emergence of resistant states remains poorly understood. Furthermore, it is unclear whether such early resistance-associated transcriptional responses are evolutionarily conserved. In this study, we examine the similarity between early transcriptional responses and long-term resistant states, assess their clinical relevance, and explore their evolutionary conservation across species. Methods: We integrated datasets on early drug responses and long-term resistance from multiple cancer cell lines, bacteria, and yeast to identify early transcriptional changes predictive of long-term resistance and assess their evolutionary conservation. Using genome-wide CRISPR-Cas9 knockout screens, we evaluated the impact of genes associated with resistant transcriptional states on drug sensitivity. Clinical datasets were analyzed to explore the prognostic value of the identified resistance-associated gene signatures. Results: We found that transcriptional states observed in drug-naive cells and shortly after treatment overlapped with those seen in fully resistant populations. Some of these shared features appear to be evolutionarily conserved. Knockout of genes marking resistant states sensitized ovarian cancer cells to Prexasertib. Moreover, early resistance gene signatures effectively distinguished therapy responders from non-responders in multiple clinical cancer trials and differentiated premalignant breast lesions that progressed to malignancy from those that remained benign. Conclusion: Early cellular transcriptional responses to therapy exhibit key similarities to fully resistant states across different drugs, cancer types, and species. Gene signatures defining these early resistance states have prognostic value in clinical settings.
- Open Access
- 5 December 2024
- Published by Springer Nature in Research Square
Non-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Incidence and severity of prostate cancer (PrCa) substantially varies across ancestries. American men of African ancestry (AA) are more likely to be diagnosed with and die from PrCa than the those of European ancestry (EA). Published polygenic risk scores for developing prostate cancer, even those based on multi-ancestry genome-wide association studies, do not address population-specific genetic mechanisms underlying PrCa risk in men of African ancestry. Specifically, the role of non-coding regulatory polymorphisms in driving inter-ancestry variation in PrCa has not been sufficiently explored. Here, by employing a sequence-based deep learning model of prostate regulatory enhancers, we identified ~ 2,000 SNPs with higher alternate allele frequency in AA men that potentially affect enhancer function associated with PrCa susceptibility, as supported by our experimental validation. The identified enhancer SNPs (eSNPs) may influence PrCa development through two complementary mechanisms: 1) the alternate allele that increase enhancer activity result in immune suppression and telomere elongation, and 2) the alternate alleles that decrease enhancer activity, lead to de-differentiation and inhibition of apoptosis. Notably, the eSNPs tend to disrupt the binding of known prostate transcription factors including FOX, AR and HOX families. Lastly, the identified eSNPs can be combined into a polygenic risk score that adds value to current GWAS-based risk variants in assessing PrCa risk in independent cohorts.
- 5 December 2024
- Published by Springer Nature in Research Square
Open AccessNon-coding genetic variants underlying higher prostate cancer risk in men of African ancestry
Incidence and severity of prostate cancer (PrCa) substantially varies across ancestries. American men of African ancestry (AA) are more likely to be diagnosed with and die from PrCa than the those of European ancestry (EA). Published polygenic risk scores for developing prostate cancer, even those based on multi-ancestry genome-wide association studies, do not address population-specific genetic mechanisms underlying PrCa risk in men of African ancestry. Specifically, the role of non-coding regulatory polymorphisms in driving inter-ancestry variation in PrCa has not been sufficiently explored. Here, by employing a sequence-based deep learning model of prostate regulatory enhancers, we identified ~ 2,000 SNPs with higher alternate allele frequency in AA men that potentially affect enhancer function associated with PrCa susceptibility, as supported by our experimental validation. The identified enhancer SNPs (eSNPs) may influence PrCa development through two complementary mechanisms: 1) the alternate allele that increase enhancer activity result in immune suppression and telomere elongation, and 2) the alternate alleles that decrease enhancer activity, lead to de-differentiation and inhibition of apoptosis. Notably, the eSNPs tend to disrupt the binding of known prostate transcription factors including FOX, AR and HOX families. Lastly, the identified eSNPs can be combined into a polygenic risk score that adds value to current GWAS-based risk variants in assessing PrCa risk in independent cohorts.
- Open Access
Resistance Signatures Manifested in Early Drug Response in Cancer and Across Species
Therapeutic resistance is a major cause of cancer treatment failure, with increasing evidence suggesting a non-genetic basis. This non-genetic resistance is often due to drug-resistant transcriptional cell states, either induced by treatment or pre-existing in some cells. However, the connection between early cellular drug response and long-term resistance is poorly understood. Moreover, it is unknown whether resistance-associated early transcriptional responses are evolutionarily conserved. Integrating long-term drug resistance and early drug response data across multiple cancer cell lines, bacteria, and yeast, our findings indicate that cancer states in drug-naive populations and shortly after treatment share transcriptional properties with fully resistant populations, some of which are evolutionarily conserved. CRISPR-Cas9 knockout of resistant states' markers increased sensitivity to Prexasertib in ovarian cancer cells. Finally, early resistant state signatures discriminated therapy responders from non-responders across multiple human cancer trials, and distinguished premalignant breast lesions that progress to malignancy from those that do not.
Open AccessResistance Signatures Manifested in Early Drug Response in Cancer and Across Species
Therapeutic resistance is a major cause of cancer treatment failure, with increasing evidence suggesting a non-genetic basis. This non-genetic resistance is often due to drug-resistant transcriptional cell states, either induced by treatment or pre-existing in some cells. However, the connection between early cellular drug response and long-term resistance is poorly understood. Moreover, it is unknown whether resistance-associated early transcriptional responses are evolutionarily conserved. Integrating long-term drug resistance and early drug response data across multiple cancer cell lines, bacteria, and yeast, our findings indicate that cancer states in drug-naive populations and shortly after treatment share transcriptional properties with fully resistant populations, some of which are evolutionarily conserved. CRISPR-Cas9 knockout of resistant states' markers increased sensitivity to Prexasertib in ovarian cancer cells. Finally, early resistant state signatures discriminated therapy responders from non-responders across multiple human cancer trials, and distinguished premalignant breast lesions that progress to malignancy from those that do not.
- Open Access
- 12 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Broad misappropriation of developmental splicing profile by cancer in multiple organs
Oncogenesis mimics key aspects of embryonic development. However, the underlying mechanisms are incompletely understood. Here, we demonstrate that the splicing events specifically active during human organogenesis, are broadly reactivated in the organ-specific tumor. Such events are associated with key oncogenic processes and predict proliferation rates in cancer cell lines as well as patient survival. Such events preferentially target nitrosylation and transmembrane-region domains, whose coordinated splicing in multiple genes respectively affect intracellular transport and N-linked glycosylation. We infer critical splicing factors potentially regulating embryonic splicing events and show that such factors are potential oncogenic drivers and are upregulated specifically in malignant cells. Multiple complementary analyses point to MYC and FOXM1 as potential transcriptional regulators of critical splicing factors in brain and liver. Our study provides a comprehensive demonstration of a splicing-mediated link between development and cancer, and suggest anti-cancer targets including splicing events, and their upstream splicing and transcriptional regulators.
- 12 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessBroad misappropriation of developmental splicing profile by cancer in multiple organs
Oncogenesis mimics key aspects of embryonic development. However, the underlying mechanisms are incompletely understood. Here, we demonstrate that the splicing events specifically active during human organogenesis, are broadly reactivated in the organ-specific tumor. Such events are associated with key oncogenic processes and predict proliferation rates in cancer cell lines as well as patient survival. Such events preferentially target nitrosylation and transmembrane-region domains, whose coordinated splicing in multiple genes respectively affect intracellular transport and N-linked glycosylation. We infer critical splicing factors potentially regulating embryonic splicing events and show that such factors are potential oncogenic drivers and are upregulated specifically in malignant cells. Multiple complementary analyses point to MYC and FOXM1 as potential transcriptional regulators of critical splicing factors in brain and liver. Our study provides a comprehensive demonstration of a splicing-mediated link between development and cancer, and suggest anti-cancer targets including splicing events, and their upstream splicing and transcriptional regulators.
- Open Access
Broad misappropriation of developmental splicing profile by cancer in multiple organs
Oncogenesis mimics key aspects of embryonic development. However, the underlying molecular determinants are not completely understood. Leveraging temporal transcriptomic data during development in multiple human organs, we demonstrate that the ‘embryonic positive (EP)’ alternative splicing events, specifically active during human organogenesis, are broadly reactivated in the organ-specific tumor. EP events are associated with key oncogenic processes and their reactivation predicts proliferation rates in cancer cell lines as well as patient survival. EP exons are significantly enriched for nitrosylation and transmembrane domains coordinately regulating splicing in multiple genes involved in intracellular transport and N-linked glycosylation respectively, known critical players in cancer. We infer critical splicing factors (CSF) potentially regulating these EP events and show that CSFs exhibit copy number amplifications in cancer and are upregulated specifically in malignant cells in the tumor microenvironment. Mutational inactivation of CSFs results in decreased EP splicing, further supporting their causal role. Multiple complementary analyses point to MYC and FOXM1 as potential transcriptional regulators of CSFs in brain and liver, which can be potentially targeted using FDA approved drugs. Our study provides the first comprehensive demonstration of a splicing-mediated link between development and cancer, and suggest novel targets including splicing events, splicing factors, and transcription factors.
Open AccessBroad misappropriation of developmental splicing profile by cancer in multiple organs
Oncogenesis mimics key aspects of embryonic development. However, the underlying molecular determinants are not completely understood. Leveraging temporal transcriptomic data during development in multiple human organs, we demonstrate that the ‘embryonic positive (EP)’ alternative splicing events, specifically active during human organogenesis, are broadly reactivated in the organ-specific tumor. EP events are associated with key oncogenic processes and their reactivation predicts proliferation rates in cancer cell lines as well as patient survival. EP exons are significantly enriched for nitrosylation and transmembrane domains coordinately regulating splicing in multiple genes involved in intracellular transport and N-linked glycosylation respectively, known critical players in cancer. We infer critical splicing factors (CSF) potentially regulating these EP events and show that CSFs exhibit copy number amplifications in cancer and are upregulated specifically in malignant cells in the tumor microenvironment. Mutational inactivation of CSFs results in decreased EP splicing, further supporting their causal role. Multiple complementary analyses point to MYC and FOXM1 as potential transcriptional regulators of CSFs in brain and liver, which can be potentially targeted using FDA approved drugs. Our study provides the first comprehensive demonstration of a splicing-mediated link between development and cancer, and suggest novel targets including splicing events, splicing factors, and transcription factors.
- Open Access
- 16 July 2021
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (7) , e1009194
Prioritizing and characterizing functionally relevant genes across human tissues
Knowledge of genes that are critical to a tissue’s function remains difficult to ascertain and presents a major bottleneck toward a mechanistic understanding of genotype-phenotype links. Here, we present the first machine learning model–FUGUE–combining transcriptional and network features, to predict tissue-relevant genes across 30 human tissues. FUGUE achieves an average cross-validation auROC of 0.86 and auPRC of 0.50 (expected 0.09). In independent datasets, FUGUE accurately distinguishes tissue or cell type-specific genes, significantly outperforming the conventional metric based on tissue-specific expression alone. Comparison of tissue-relevant transcription factors across tissue recapitulate their developmental relationships. Interestingly, the tissue-relevant genes cluster on the genome within topologically associated domains and furthermore, are highly enriched for differentially expressed genes in the corresponding cancer type. We provide the prioritized gene lists in 30 human tissues and an open-source software to prioritize genes in a novel context given multi-sample transcriptomic data.
- 16 July 2021
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 17 (7) , e1009194
Open AccessPrioritizing and characterizing functionally relevant genes across human tissues
Knowledge of genes that are critical to a tissue’s function remains difficult to ascertain and presents a major bottleneck toward a mechanistic understanding of genotype-phenotype links. Here, we present the first machine learning model–FUGUE–combining transcriptional and network features, to predict tissue-relevant genes across 30 human tissues. FUGUE achieves an average cross-validation auROC of 0.86 and auPRC of 0.50 (expected 0.09). In independent datasets, FUGUE accurately distinguishes tissue or cell type-specific genes, significantly outperforming the conventional metric based on tissue-specific expression alone. Comparison of tissue-relevant transcription factors across tissue recapitulate their developmental relationships. Interestingly, the tissue-relevant genes cluster on the genome within topologically associated domains and furthermore, are highly enriched for differentially expressed genes in the corresponding cancer type. We provide the prioritized gene lists in 30 human tissues and an open-source software to prioritize genes in a novel context given multi-sample transcriptomic data.
- Open Access
- 16 February 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (2) , e1009354
Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells
TheRB1tumor suppressor is recurrently mutated in a variety of cancers including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Finding new synthetic lethal (SL) interactions withRB1could lead to new approaches to treating cancers with inactivatedRB1. We identified 95 SL partners ofRB1based on aDrosophilascreen for genetic modifiers of the eye phenotype caused by defects in theRB1ortholog,Rbf1. We validated 38 mammalian orthologs ofRbf1modifiers as RB1 SL partners in human cancer cell lines with defectiveRB1alleles. We further show that for many of theRB1SL genes validated in human cancer cell lines, low activity of the SL gene in human tumors, when concurrent with low levels ofRB1was associated with improved patient survival. We investigated higher order combinatorial gene interactions by creating a novelDrosophilacancer model with co-occurringRbf1,PtenandRasmutations, and found that targeting RB1 SL genes in this background suppressed the dramatic tumor growth and rescued fly survival whilst having minimal effects on wild-type cells. Finally, we found that drugs targeting the identified RB1 interacting genes/pathways, such as UNC3230, PYR-41, TAK-243, isoginkgetin, madrasin, and celastrol also elicit SL in human cancer cell lines. In summary, we identified several high confidence, evolutionarily conserved, novel targets forRB1-deficient cells that may be further adapted for the treatment of human cancer.
- 16 February 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (2) , e1009354
Open AccessCross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells
TheRB1tumor suppressor is recurrently mutated in a variety of cancers including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate cancers, and osteosarcomas. Finding new synthetic lethal (SL) interactions withRB1could lead to new approaches to treating cancers with inactivatedRB1. We identified 95 SL partners ofRB1based on aDrosophilascreen for genetic modifiers of the eye phenotype caused by defects in theRB1ortholog,Rbf1. We validated 38 mammalian orthologs ofRbf1modifiers as RB1 SL partners in human cancer cell lines with defectiveRB1alleles. We further show that for many of theRB1SL genes validated in human cancer cell lines, low activity of the SL gene in human tumors, when concurrent with low levels ofRB1was associated with improved patient survival. We investigated higher order combinatorial gene interactions by creating a novelDrosophilacancer model with co-occurringRbf1,PtenandRasmutations, and found that targeting RB1 SL genes in this background suppressed the dramatic tumor growth and rescued fly survival whilst having minimal effects on wild-type cells. Finally, we found that drugs targeting the identified RB1 interacting genes/pathways, such as UNC3230, PYR-41, TAK-243, isoginkgetin, madrasin, and celastrol also elicit SL in human cancer cell lines. In summary, we identified several high confidence, evolutionarily conserved, novel targets forRB1-deficient cells that may be further adapted for the treatment of human cancer.